CRP
ZECEN
| Quantity: | |
|---|---|
SUMMARY AND EXPLANATION OF THE TEST
C-reactive protein (CRP) detection kit (CLIA) (hereinafter referred to as the kit), is used for the in vitro quantitative determination of C-reactive protein (CRP) concentration in human serum. It can be used to diagnose the infection, tissue damage and inflammatory disease, which can also be used as an adjunct to cardiovascular disease risk identification. C-reactive protein (CRP) is synthesized by hepatocytes in the fetal stage, and not transferred by maternal placental. Its generation mechanism is: when the body is infected or tissue injured, macrophages and other white blood cells are activated to produce interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor (TNF-a) other cytokines and other mediators. These cytokines and mediators reach the liver, and stimulate the liver cells and epithelial cells to synthesize CRP. In the structure, CRP contains 5 polypeptide chain subunits, and non-covalent binds into the disc-shaped polymer with a molecular weight of 115,000-140,000. CRP is a typical acute-phase protein.
PRINCIPLE OF THE TEST
Sandwich method: CRP Antibody labeled by FITC and CRP Antibody pair labeled by AP bind with the CRP antigen in the sample, control or calibrator and form sandwich complex. Then add the magnetic beads binding with Anti-FITC, through the specific binding between the FITC and Anti-FITC, the complex will be bound by the magnetic beads. Then the entire complex will be captured by the external applied magnetic field and separate from the unbound substance. After washing, add the substrate. The substrate will be catalytically cracked under the action of the enzyme, and form an unstable intermediate in excited state. When the intermediate in excited state returns to the ground state, it will issue photons and make a light-emitting reaction. Then the CLIA analyzer will measure the luminous intensity and count the results through software by comparing the luminous intensity with the cutoff value to determine whether the corresponding antibody exists.
SUMMARY AND EXPLANATION OF THE TEST
C-reactive protein (CRP) detection kit (CLIA) (hereinafter referred to as the kit), is used for the in vitro quantitative determination of C-reactive protein (CRP) concentration in human serum. It can be used to diagnose the infection, tissue damage and inflammatory disease, which can also be used as an adjunct to cardiovascular disease risk identification. C-reactive protein (CRP) is synthesized by hepatocytes in the fetal stage, and not transferred by maternal placental. Its generation mechanism is: when the body is infected or tissue injured, macrophages and other white blood cells are activated to produce interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor (TNF-a) other cytokines and other mediators. These cytokines and mediators reach the liver, and stimulate the liver cells and epithelial cells to synthesize CRP. In the structure, CRP contains 5 polypeptide chain subunits, and non-covalent binds into the disc-shaped polymer with a molecular weight of 115,000-140,000. CRP is a typical acute-phase protein.
PRINCIPLE OF THE TEST
Sandwich method: CRP Antibody labeled by FITC and CRP Antibody pair labeled by AP bind with the CRP antigen in the sample, control or calibrator and form sandwich complex. Then add the magnetic beads binding with Anti-FITC, through the specific binding between the FITC and Anti-FITC, the complex will be bound by the magnetic beads. Then the entire complex will be captured by the external applied magnetic field and separate from the unbound substance. After washing, add the substrate. The substrate will be catalytically cracked under the action of the enzyme, and form an unstable intermediate in excited state. When the intermediate in excited state returns to the ground state, it will issue photons and make a light-emitting reaction. Then the CLIA analyzer will measure the luminous intensity and count the results through software by comparing the luminous intensity with the cutoff value to determine whether the corresponding antibody exists.
